Pulmonary Division, Rabin Medical Center, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Thorac Cancer. 2022 Jun;13(11):1592-1596. doi: 10.1111/1759-7714.14422. Epub 2022 Apr 26.
The diagnostic yield of endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) from mediastinal lymph nodes ranges from 66%-89%. However, in many cases cytologic material is not sufficient for full molecular evaluation. A novel method of transcarinal cryobiopsy aims to provide bronchoscopically obtained, larger specimen samples from mediastinal lymph nodes. We aimed to assess the efficacy and safety of transcarinal EBUS-guided lymph node cryobiopsy.
Patients referred for EBUS-TBNA, based on abnormal mediastinal clinical and radiographic findings, were enrolled into this prospective interventional study between July 2020 and August 2021. All EBUS-TBNA procedures were performed using ProCore 22G needle (Cook Medical) to create, both a transcarinal tract for the cryoprobe and to obtain TBNA samples. For EBUS guided transcarinal cryobiopsy, we used flexible 1.1 mm or 1.7 mm cryoprobe inserted into the working channel of the EBUS scope and into the target subcarinal lymph node.
Twenty-four patients with male predominance 2:1 and mean age of 60.12 ± 10.16 years were enrolled. All target lymph nodes had hypoechoic, homogenic consistency with demarcated borders, without central structures. Cryobiopsy provided pathological diagnosis in 20 cases (83.33%), with 1.1 mm cryoprobe in 14 and with 1.7 mm cryoprobe in 6 cases. In one case each, pathology was provided by TBNA or by cryoprobe alone. No immediate or late complications were encountered during the procedures.
Transcarinal EBUS guided lymph node cryobiopsy following EBUS-TBNA proved to be efficient with a high diagnostic yield and can be considered safe, because no immediate or late complications occurred.
经支气管超声引导针吸活检术(EBUS-TBNA)从纵隔淋巴结获取的诊断率为 66%-89%。然而,在许多情况下,细胞学材料不足以进行全面的分子评估。一种新的经隆突冷冻活检方法旨在提供支气管获得的、来自纵隔淋巴结的更大标本样本。我们旨在评估经隆突 EBUS 引导下淋巴结冷冻活检的疗效和安全性。
2020 年 7 月至 2021 年 8 月,我们对因纵隔临床和影像学异常而接受 EBUS-TBNA 的患者进行了这项前瞻性介入研究。所有 EBUS-TBNA 操作均使用 ProCore 22G 针(库克医疗)进行,以创建经隆突通道和获取 TBNA 样本。对于 EBUS 引导下的经隆突冷冻活检,我们使用柔性 1.1mm 或 1.7mm 冷冻探针插入 EBUS 镜的工作通道并进入目标隆突下淋巴结。
24 例患者中男性占 2:1,平均年龄为 60.12±10.16 岁。所有目标淋巴结均为低回声、同质、边界清晰,无中央结构。冷冻活检在 20 例(83.33%)中提供了病理诊断,其中 1.1mm 冷冻探针 14 例,1.7mm 冷冻探针 6 例。各有 1 例分别由 TBNA 或冷冻探针提供病理诊断。在操作过程中未发生即时或迟发性并发症。
在 EBUS-TBNA 之后进行经隆突 EBUS 引导下淋巴结冷冻活检,证明是有效的,具有较高的诊断率,并且可以认为是安全的,因为没有发生即时或迟发性并发症。